MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy

Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 913-929

  Bobustuc, George C ^a,b,c,d   Smith, Joshua S ^a   Maddipatla, Sreeram ^a   Jeudy, Sheila ^a   Limaye, Arati ^a   Isley, Beth ^a   Caparas, Maria Lourdes M ^a   Constantino, Susan M ^a   Shah, Nikita ^a,c   Baker, Cheryl H ^b   Srivenugopal, Kalkunte S ^e   Baidas, Said ^a,c   Konduri, Santhi D ^a,c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Advanced Healthcare   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PUMA PROTEIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; PHOSPHORYLATION; PHOSPHOSERINE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84865266059     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00010     Document Type: Article

References (66)

1. Masood S. (1992) Use of monoclonal antibody for assessment of estrogen and progesterone receptors in malignant effusions. Diagn. Cytopathol. 8:161-6.
2. McDonnell DP, Norris JD. (2002) Connections and regulation of the human estrogen receptor. Science. 296:1642-4.
3. Sommer S, Fuqua SA. (2001) Estrogen receptor and breast cancer. Semin. Cancer Biol. 11:339-52.
4. Ali S, Coombes RC. (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer. 2:101-12.
5. Lipton A, et al. (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 104:257-63.
6. Sarwar N, et al. (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr. Relat. Cancer. 13:851-61.
7. Yamashita H, et al. (2008) Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr. Relat. Cancer. 15:755-63.
8. Yamashita H, et al. (2005) Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 7:R753-64.
9. Jiang J, et al. (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 13:5769-76.
10. Motomura K, et al. (2010) Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology. 79:55-61.
11. Joel PB, Traish AM, Lannigan DA. (1998) Estradiolinduced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogenactivated protein kinase. J. Biol. Chem. 273:13317-23.
12. Shou J, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96:926-35.
13. Font de Mora J, Brown M. (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20:5041-7.
14. Osborne CK, et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95:353-61.
15. Motomura K, et al. (2010) Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology. 79:55-61.
16. Shang Y, Brown M. (2002) Molecular determinants for the tissue specificity of SERMs. Science. 295:2465-8.
17. Fisher B, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-88.
18. Veronesi U, et al. (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in highrisk women. J Natl. Cancer Inst. 95:160-5.
19. Early Breast Cancer Trialists' Collaborative Group. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet. 339(8784):1-15. See also 339(8785):71-85.
20. Early Breast Cancer Trialists' Collaborative Group. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1451-67.
21. Love R. (1989) Identification of high-risk groups and preventive strategies. Curr. Opin. Oncol. 1:284-7.
22. Thurlimann B, et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353:2747-57.
23. Baum M, et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2131-9.
24. Coombes RC, et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350:1081-92.
25. Goss PE, et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349:1793-802.
26. Winer EP, et al. (2002) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol. 20:3317-27.
27. Ravdin P. (2002) Aromatase inhibitors for the en-docrine adjuvant treatment of breast cancer. Lancet. 359:2126-7.
28. Chlebowski RT, et al. (2002) American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol. 20:3328-43.
29. Clarke R, Leonessa F, Welch JN, Skaar TC. (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53:25-71.
30. Moy B, Goss PE. (2006) Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin. Cancer Res. 12:4790-3.
31. Osborne CK, Shou J, Massarweh S, Schiff R. (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. 11:865s-70s.
32. Jordan VC. (2004) Selective estrogen recepto modulation: concept and consequences in cancer. Cancer Cell. 5:207-13.
33. Holm C, et al. (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl. Cancer Inst. 98:671-80.
34. Shi L, et al. (2009) Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27:3423-9.
35. Preuss I, et al. (1996) Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. Cancer Detect. Prev. 20:130-6.
36. Wani G, D'Ambrosio SM. (1997) Expression of the O6-alkylguanine-DNA alkyltransferase gene is elevated in human breast tumor cells. Anticancer Res. 17:4311-5.
37. Citron M, et al. (1994) O6-methylguanine-DNA methyltransferase in normal and malignant tissue of the breast. Cancer Invest. 12:605-10.
38. Preuss I, et al. (1995) O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int. J. Cancer. 61:321-6.
39. Dolan ME, et al. (1991) Effect of O6-benzylgua nine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 51:3367-72.
40. Dolan ME, Moschel RC, Pegg AE. (1990) Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. U. S. A. 87:5368-72.
41. Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE. (1990) Modulation of mammalian O6alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 2:371-7.
42. Pegg AE, et al. (1993) Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry. 32:11998-2006.
43. Chahal M, et al. (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro. Oncol. 12:822-33.
44. Niture SK, et al. (2005) Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem. Biophys. Res. Commun. 337:1176-84.
45. Yan L, Donze JR, Liu L. (2005) Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene. 24:2175-83.
46. Osanai T, et al. (2005) Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn. J. Clin. Oncol. 35:121-5.
47. Harris LC, Remack JS, Houghton PJ, Brent TP. (1996) Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 56:2029-32.
48. Bobustuc GC, et al. (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro. Oncol. 12:917-27.
49. Konduri SD, et al. (2010) Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc. Natl. Acad. Sci. U. S. A. 107:15081-6.
50. Nawata H, Bronzert D, Lippman ME. (1981) Isolation and characterization of a tamoxifen-resistant cell line derived from MCF7 human breast cancer cells. J. Biol. Chem. 256:5016-21.
51. Lykkesfeldt AE, Madsen MW, Briand P. (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF7/TAMR-1. Cancer Res. 54:1587-95.
52. Konduri S, et al. (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol. Cancer Ther. 8:533-42.
53. Konduri SD, et al. (2009) Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin. Cancer Res. 15:6087-95.
54. Smith JS, et al. (2010) Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells. Anticancer Agents Med. Chem. 10:644-50.
55. Gong J, Ammanamanchi S, Ko TC, Brattain MG. (2003) Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res. 63:3340-6.
56. Liu W, et al. (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem. 281:9837-40.
57. Sayeed A, et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 67:7746-55.
58. Myrnes B, et al. (1984) A simplified assay for O6methylguanine-DNA methyltransferase activity and its application to human neoplastic and nonneoplastic tissues. Carcinogenesis. 5:1061-4.
59. Srivenugopal KS, et al. (2000) Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells. Cancer Res. 60:282-7.
60. Tuominen VJ, et al. (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12:R56.
61. Ward RD, Weigel NL. (2009) Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors. 35:528-36.
62. Shou W, et al. (2002) Mapping phosphorylation sites in proteins by mass spectrometry. Methods Enzymol. 351:279-96.
63. Angeloni SV, et al. (2004) Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF7 cells. J. Endocrinol. 180:497-504.
64. Fuchs-Young R, et al. (2011) P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res. Treat. 130:399-408.
65. Rasti M, Arabsolghar R, Khatooni Z, MostafaviPour Z. (2012) p53 binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol. Oncol. Res. 18:169-75.
66. Shirley SH, et al. (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 69:3405-14.